Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 3 22Phase 1 8Phase 1/2 4Phase 2/3 3

Status

Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Pathologic Complete Response 1Colonic Neoplasms 1

Interventions

pembrolizumab 35Carboplatin 24Specimen Handling 20Cyclophosphamide 19Magnetic Resonance Spectroscopy 18fludarabine 15Dexamethasone 15Nivolumab 14Gemcitabine 14Bevacizumab 14Biopsy 12atezolizumab 11Temozolomide 11Paclitaxel 10Docetaxel 10Cisplatin 10venetoclax 9Rituximab 9Pemetrexed 9Ipilimumab 9Prednisone 8Lenalidomide 8Fluorouracil 8blinatumomab 7Vincristine 7Radiotherapy 7Oxaliplatin 7Capecitabine 7olaparib 6lenvatinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × durvalumab × 30 days × Clear all
NCT04748419 2026-06-05

Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab

University of Nebraska

Phase 1/2 Terminated
6 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT06287775 2026-05-22

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
45 enrolled
Thoracic

Lung Neoplasms

NCT04068610 2026-05-15

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

MedImmune LLC

Phase 1/2 Active not recruiting
61 enrolled 35 charts
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡